Genprex

News

Genprex to Present at Upcoming September Investor Conference  

Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Read More

Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers

Intellectual Property Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial

Read More


Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit

Company Manufacturing Leads Selected as Thought Leaders to Discuss Advances in Lipid Nanoparticle Delivery Systems

Read More

Genprex to Present at Upcoming June Investor Conferences

Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Read More

Genprex to Present at Upcoming Investor Conference in May 2022

Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Read More

Genprex’s Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference

Live panel discussion will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in solid tumors

Read More

Genprex Issues Shareholder Letter and Provides 2022 Corporate Update

Company achieves major milestones in clinical development programs in 2022

Patient treatment in Acclaim-2 clinical trial commences

Read More

Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022

Presentations to highlight the Company’s gene therapies for cancer and diabetes

Read More